Education
About Us
Working with TipRanks
Follow Us
Nuwellis (NUWE)
NASDAQ:NUWE
NUWE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.82 - $175.98
Previous CloseN/A
Volume102.02K
Average Volume (3M)199.99K
Market Cap
$4.60M
Enterprise Value-$2.10M
Total Cash (Recent Filing)$4.45M
Total Debt (Recent Filing)$438.00K
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Nov 11, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-60.99
Shares Outstanding902,665
10 Day Avg. Volume219,901
30 Day Avg. Volume199,992
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.46
Enterprise Value/Revenue-0.25
Enterprise Value/Gross Profit-0.42
Enterprise Value/Ebitda0.53
Forecast
1Y Price Target
$5.50Price Target Upside7.84% Upside
Rating ConsensusHold
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Pediatric RevenueStrong growth in Pediatric revenue, up 28% year-over-year, following the addition of three new accounts during the quarter.
ReimbursementThe CMS will reassign the Aquadex ultrafiltration code to increase reimbursement rates, which should provide a profitable reimbursement pathway and expand the number of patients who can receive the therapy.
Revenue GrowthThe slight revenue beat in 2Q24 is a positive sign that the company is expanding its presence within the medical system and driving increased utilization of consumables.
Bears Say
Cash FlowEven with the higher reimbursement rates, the company is not expected to operate on a positive cash flow basis through at least 2026.
Pediatric UtilizationThe y/y decline in the quarter in pediatric utilization gives some concern.
ProfitabilityThe timeline towards profitability remains unclear, likely requiring additional dilutive capital raises, which dampens the investment outlook.
Nuwellis News
NUWE FAQ
What was Nuwellis’s price range in the past 12 months?
Nuwellis lowest stock price was $4.82 and its highest was $175.98 in the past 12 months.
What is Nuwellis’s market cap?
Nuwellis’s market cap is $4.60M.
When is Nuwellis’s upcoming earnings report date?
Nuwellis’s upcoming earnings report date is Nov 11, 2025 which is in 69 days.
How were Nuwellis’s earnings last quarter?
Nuwellis released its earnings results on Aug 14, 2025. The company reported -$60.99 earnings per share for the quarter, missing the consensus estimate of -$18.9 by -$42.09.
Is Nuwellis overvalued?
According to Wall Street analysts Nuwellis’s price is currently Undervalued.
Does Nuwellis pay dividends?
Nuwellis does not currently pay dividends.
What is Nuwellis’s EPS estimate?
Nuwellis’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nuwellis have?
Nuwellis has 902,665 shares outstanding.
What happened to Nuwellis’s price movement after its last earnings report?
Nuwellis reported an EPS of -$60.99 in its last earnings report, missing expectations of -$18.9. Following the earnings report the stock price went up 2.545%.
Which hedge fund is a major shareholder of Nuwellis?
Currently, no hedge funds are holding shares in NUWE
Company Description
Nuwellis
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
NUWE Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Negative
The earnings call highlights several strategic initiatives and resolutions, such as pediatric revenue growth and successful transition plans, which are promising for future growth. However, the current financial performance is challenged by a significant revenue decline, reduced gross margins, and increased operating losses. While there are positive steps being taken, the immediate financial indicators present a negative outlook.View all NUWE earnings summariesTechnical Analysis
Sintx Technologies
―
Vyome Holdings
―
Venus Concept
―
Catheter Precision
―
Autonomix Medical, Inc.
―
Ownership Overview
23.01% Insiders
0.75% Mutual Funds
0.95% Other Institutional Investors
75.25% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---